Oramed Pharmaceuticals (NASDAQ:ORMP) versus Evolus (NASDAQ:EOLS) Head to Head Analysis

Evolus (NASDAQ:EOLS) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings for Evolus and Oramed Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1	1	4	0	2.50
Oramed Pharmaceuticals	0	1	0	0	2.00

Evolus presently has a consensus target price of $16.00, suggesting a potential upside of 260.36%. Given Evolus’ stronger consensus rating and higher possible upside, analysts clearly believe Evolus is more favorable than Oramed Pharmaceuticals.

Insider & Institutional Ownership

90.7% of Evolus shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 6.1% of Evolus shares are owned by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Evolus has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Oramed Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Valuation & Earnings

This table compares Evolus and Oramed Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18 million	0.97	-$51.64 million	($0.81)	-5.48
Oramed Pharmaceuticals	$2.00 million	76.86	$64.05 million	$1.49	2.55

Oramed Pharmaceuticals has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evolus and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evolus	-17.38%	N/A	-21.57%
Oramed Pharmaceuticals	N/A	-6.83%	-6.25%

Summary

Oramed Pharmaceuticals beats Evolus on 8 of the 14 factors compared between the two stocks.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.